Clinical Trials Logo

Metastatic Cervical Cancer clinical trials

View clinical trials related to Metastatic Cervical Cancer.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06313268 Recruiting - Clinical trials for Metastatic Colorectal Cancer

Safety of Effivia®, a Bevacizumab Biosimilar

Start date: April 21, 2022
Phase:
Study type: Observational [Patient Registry]

This is a post-marketing observational study aimed to evaluated the safety profile of Effivia®, a biosimilar of bevacizumab, in mexican patients with different types of cancer.

NCT ID: NCT06238635 Recruiting - Cervical Cancer Clinical Trials

Dostarlimab and Cobolimab in Advanced Cervical Cancer

Start date: March 11, 2024
Phase: Phase 2
Study type: Interventional

This research is being done to determine how effective dostarlimab in combination with cobolimab is in metastatic or recurrent cervical cancer.

NCT ID: NCT05446883 Recruiting - Clinical trials for METASTATIC CERVICAL CANCER

QL1706 Plus Chemotherapy±Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer

Start date: September 23, 2022
Phase: Phase 3
Study type: Interventional

This study is a randomized, double-blind, placebo-controlled, multicenter phase III clinical study in 498 patients with persistent, recurrent or metastatic cervical cancer.Experimental: QL1706 + Chemotherapy (Paclitaxel-cisplatin/Carboplatin) ± Bevacizumab; Control group: placebo + chemotherapy (paclitaxel-cisplatin/carboplatin) ± bevacizumab

NCT ID: NCT04865887 Recruiting - Cervical Cancer Clinical Trials

Pembrolizumab and Lenvatinib in Advanced Cervical Cancer

Start date: October 7, 2022
Phase: Phase 2
Study type: Interventional

This is a phase II trial of combination therapy of pembrolizumab and lenvatinib in patients with locally advanced or metastatic cervical cancer that had failed first line of therapy. The hypothesis is the combination of lenvatinib and pembrolizumab will overcome vascular endothelial growth factor (VEGF)-mediated immunosuppression to enhance the response of patients with locally advanced or metastatic cervical cancer.

NCT ID: NCT00532818 Recruiting - Clinical trials for Metastatic Cervical Cancer

Hydralazine Valproate for Cervical Cancer

Start date: July 2007
Phase: Phase 3
Study type: Interventional

The current standard for recurrent, persistent or metastatic cervical cancer is palliative chemotherapy with cisplatin topotecan, however, the results need to be improved. Epigenetic aberrations play an important role in cancer progression by silencing growth regulatory genes and there is now evidence that inhibitors of DNA methylation and HDAC inhibition synergize the cytotoxicity of chemotherapy. Objective. To determine the superiority of epigenetic therapy with hydralazine and valproate plus standard cisplatin topotecan against placebo plus cisplatin topotecan upon progression-free survival. Hypothesis. Hydralazine and magnesium valproate associated to cisplatin topotecan will increase progression-free survival from 4.6 to 7.6 months as compared with the same regimen of chemotherapy plus placebo.